{'fraction_non_alphanumeric': 0.05172413793103448, 'fraction_numerical': 0.03864447086801427, 'mean_word_length': 4.763698630136986, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Budget Impact Analysis of the Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease in the EU-5 Countries


 Background: In 2020, the European Medicines Agency approved CT-P13 subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget impact analysis of introducing CT-P13 SC to the EU-5 market for 5 years, from the healthcare payer’s perspective.Methods: A prevalence-based budget impact model was developed to examine the financial impact of CT-P13 SC. “World with” versus “world without” CT-P13 SC scenarios were compared, including the potential administration costs of IV administration.Results: Introducing CT-P13 SC in patients with Crohn’s disease (CD) for 5 years resulted in cost savings of €42.0 million in the UK, €59.4 million in Germany, and €46.4 million in France and Italy, but increased budget expenditure in Spain by €3.8 million. For ulcerative colitis (UC), cost savings of €42.7 million in the UK, €44.9 million in Germany, €44.3 million in France, and €53.0 million in Italy occurred, but with no savings in Spain for 5 years. Cost-savings per patient was calculated by diving the net budget saving by number of treatment eligible patients. Maximum and minimum saving per patient per year ranged between €38.25 and €575.74 in CD, both from Germany, and €105.06 (France) and €647.25 (Germany) in UC.Conclusion: Healthcare payers in the UK, Germany, France, and Italy, but not in Spain, will make budget savings by using CT-P13 SC for the treatment of inflammatory bowel disease.